businesspress24.com - Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Pub
 

Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")

ID: 1163047

Regulated Information

(firmenpresse) - GHENT, BELGIUM -- (Marketwire) -- 10/23/12 -- today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Sofinnova Partners SAS and Gilde Europe Food & Agribusiness Fund BV.

Sofinnova Partners SAS has dropped below the 15% threshold and Gilde Europe Food & Agribusiness Fund BV has dropped below the 3% threshold.

Full versions of all transparency notifications are available on the website of Ablynx, section Investors.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on .

pdf version of the press release :



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e:




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Tonix Pharmaceuticals Confirms Clinical Utility of TNX-102 Sublingual Tablet
Last Chance to Attend 'Clinical Trials in Georgia' Conference on Nov. 2, 2012
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 23.10.2012 - 11:02 Uhr
Sprache: Deutsch
News-ID 1163047
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

GHENT, BELGIUM


Phone:

Kategorie:

Trials


Anmerkungen:


Diese Pressemitteilung wurde bisher 299 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")
"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ablynx



 

Who is online

All members: 10 564
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 50


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.